Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.3
4.1
Journals
Metabolites
Special Issues
Biomarkers for Metabolism and Cardiometabolic Diseases
share announcement

Biomarkers for Metabolism and Cardiometabolic Diseases

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 13312

Special Issue Editor

Prof. Dr. Pollen K. Yeung

E-Mail Website
Guest Editor
Professor of Pharmacy and Medicine, College of Pharmacy, Dalhousie University, Halifax, NS B3H 4R2, Canada
Interests: cardiovascular medicine; pharmacy; pharmacokinetics; biomarkers; pharmacology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomarkers are objective and quantitatively measurable indicators of biological or pathogenic processes and can include small molecular entities as well as large molecular weight proteins and genetic materials. Biomarkers are increasingly used in drug discovery and development, the diagnosis of diseases, managing disease progression, and practicing precision medicine. This Special Issue is devoted to the application of biomarkers for the management of cardiovascular and metabolic diseases, the development of drugs and therapeutics, and managing disease progression and prognosis. Topics covered by this Special Issue will include (though not exclusively) the identification of metabolites and/or biomarkers as targets for drugs and natural health products; the validation of targets derived from biomarkers; metabolites and/or biomarkers as therapeutics; and biomarkers for drug development, disease modeling and management, and precision medicine. We anticipate that it will be a timely topic in the fight against the worldwide COVID-19 infection, which is known to be highly impacted by metabolism and cardiovascular diseases.

Prof. Dr. Pollen K. Yeung
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • drugs
  • natural health products
  • metabolites
  • therapeutics
  • cardiometabolic diseases

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 285 KiB  
Article
Relationship of Inflammatory Markers and Metabolic Syndrome in Postmenopausal Women
by Renata Vargas Sinatora, Eduardo Federighi Baisi Chagas, Fernando Otavio Pires Mattera, Luciano Junqueira Mellem, Ana Rita de Oliveira dos Santos, Larissa Pires Pereira, Ana Luíza de Carvalho Aranão, Elen Landgraf Guiguer, Adriano Cressoni Araújo, Jesselina F. dos Santos Haber, Leila Campos Guissoni and Sandra Maria Barbalho
Metabolites 2022, 12(1), 73; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo12010073 - 13 Jan 2022
Cited by 8 | Viewed by 1818
Abstract
The increased deposition of visceral fat in the postmenopause period increases the production of inflammatory cytokines and the release of tumor necrosis factor- α (TNF-α), interleukin-6 (IL-6), and decrease in IL-10. This study investigated the relationship between inflammatory biomarkers and metabolic syndrome (MS) [...] Read more.
The increased deposition of visceral fat in the postmenopause period increases the production of inflammatory cytokines and the release of tumor necrosis factor- α (TNF-α), interleukin-6 (IL-6), and decrease in IL-10. This study investigated the relationship between inflammatory biomarkers and metabolic syndrome (MS) in postmenopausal women considering different diagnostic criteria. We conducted a cross-sectional observational study based on STROBE. Data were collected regarding the diagnostic criteria for MS (International Diabetes Federation; NCEP (International Diabetes Federation (IDF), National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III), and Harmonized criteria), body composition, comorbidities, time without menstruation, values of IL-6, IL-10, and TNF-α. ANOVA, Kruskal–Wallis, Levene tests, ROC, and odds ratio were performed to analyze the data. The results showed no significant difference between the methods and no interaction between the method and the presence of MS. However, for the values of WC, body fat percentage, TNF-α, and IL-10/TNF-α ratio, a significant effect of MS was observed. In subjects with MS, lower values of body fat percentage and TNF-α and higher values of the IL-10/TNF-α ratio were also observed. The higher IL-10/TNF-α ratio in the MS group is related to the greater anti-inflationary action of IL-10. The IL-10/TNF-α ratio showed significant accuracy to discriminate patients with MS according to the NCEP-ATP III criteria. Full article
(This article belongs to the Special Issue Biomarkers for Metabolism and Cardiometabolic Diseases)
13 pages, 1792 KiB  
Article
Identification of Circulating Diagnostic Biomarkers for Coronary Microvascular Disease in Postmenopausal Women Using Machine-Learning Techniques
by Alicia Arredondo Eve, Elif Tunc, Yu-Jeh Liu, Saumya Agrawal, Huriye Erbak Yilmaz, Sadık Volkan Emren, Filiz Akyıldız Akçay, Luidmila Mainzer, Justina Žurauskienė and Zeynep Madak Erdogan
Metabolites 2021, 11(6), 339; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo11060339 - 25 May 2021
Cited by 3 | Viewed by 4029
Abstract
Coronary microvascular disease (CMD) is a common form of heart disease in postmenopausal women. It is not due to plaque formation but dysfunction of microvessels that feed the heart muscle. The majority of the patients do not receive a proper diagnosis, are discharged [...] Read more.
Coronary microvascular disease (CMD) is a common form of heart disease in postmenopausal women. It is not due to plaque formation but dysfunction of microvessels that feed the heart muscle. The majority of the patients do not receive a proper diagnosis, are discharged prematurely and must go back to the hospital with persistent symptoms. Because of the lack of diagnostic biomarkers, in the current study, we focused on identifying novel circulating biomarkers of CMV that could potentially be used for developing a diagnostic test. We hypothesized that plasma metabolite composition is different for postmenopausal women with no heart disease, CAD, or CMD. A total of 70 postmenopausal women, 26 healthy individuals, 23 individuals with CMD and 21 individuals with CAD were recruited. Their full health screening and tests were completed. Basic cardiac examination, including detailed clinical history, additional disease and prescribed drugs, were noted. Electrocardiograph, transthoracic echocardiography and laboratory analysis were also obtained. Additionally, we performed full metabolite profiling of plasma samples from these individuals using gas chromatography-mass spectrometry (GC–MS) analysis, identified and classified circulating biomarkers using machine learning approaches. Stearic acid and ornithine levels were significantly higher in postmenopausal women with CMD. In contrast, valine levels were higher for women with CAD. Our research identified potential circulating plasma biomarkers of this debilitating heart disease in postmenopausal women, which will have a clinical impact on diagnostic test design in the future. Full article
(This article belongs to the Special Issue Biomarkers for Metabolism and Cardiometabolic Diseases)
►▼ Show Figures

Figure 1

12 pages, 2527 KiB  
Article
Lysophospholipids as Predictive Markers of ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI)
by Elin Chorell, Tommy Olsson, Jan-Håkan Jansson and Patrik Wennberg
Metabolites 2021, 11(1), 25; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo11010025 - 31 Dec 2020
Cited by 9 | Viewed by 6811
Abstract
The present study explored patterns of circulating metabolites and proteins that can predict future risk for ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). We conducted a prospective nested case-control study in northern Sweden in individuals who developed STEMI (N = 50) [...] Read more.
The present study explored patterns of circulating metabolites and proteins that can predict future risk for ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). We conducted a prospective nested case-control study in northern Sweden in individuals who developed STEMI (N = 50) and NSTEMI (N = 50) within 5 years and individually matched controls (N = 100). Fasted plasma samples were subjected to multiplatform mass spectrometry-based metabolomics and multiplex protein analyses. Multivariate analyses were used to elucidate infarction-specific metabolite and protein risk profiles associated with future incident STEMI and NSTEMI. We found that altered lysophosphatidylcholine (LPC) to lysophosphatidylethanolamine (LPE) ratio predicted STEMI and NSTEMI events in different ways. In STEMI, lysophospholipids (mainly LPEs) were lower, whereas in NSTEMI, lysophospholipids (mainly LPEs) were higher. We found a similar response for all detected lysophospholipids but significant alterations only for those containing linoleic acid (C18:2, p < 0.05). Patients with STEMI had higher secretoglobin family 3A member 2 and tartrate-resistant acid phosphate type 5 and lower platelet-derived growth factor subunit A, which are proteins associated with atherosclerosis severity and plaque development mediated via altered phospholipid metabolism. In contrast, patients with NSTEMI had higher levels of proteins associated with inflammation and macrophage activation, including interleukin 6, C-reactive protein, chemerin, and cathepsin X and D. The STEMI risk marker profile includes factors closely related to the development of unstable plaque, including a higher LPC:LPE ratio, whereas NSTEMI is characterized by a lower LPC:LPE ratio and increased inflammation. Full article
(This article belongs to the Special Issue Biomarkers for Metabolism and Cardiometabolic Diseases)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop